Glintt Global achieved a consolidated net profit of 4.7 million euros in the first half of 2026, a 21.3% growth compared to the 3.9 million euros recorded in the same period of 2025. Turnover reached 75.8 million euros, an 11.2% increase driven by the domestic market, which grew 13.5%, and by the international market, with a 7.3% advance.
EBITDA remained practically stable at 11.2 million euros, a slight decline of 0.5%, with the EBITDA margin falling from 16.6% to 14.8%. This decrease reflects the increase in personnel costs, associated with the reinforcement of investment in talent retention and qualification and the growth in the number of employees. The jump in net profit was explained by the 43.6% reduction in financial charges, to 876 thousand euros, due to the improvement in the group's financing conditions.
Financial autonomy stood at 44.2% at the end of June, 2.5 percentage points more than a year earlier, although below the 46.2% of December 2025, due to the distribution of 5.8 million euros in dividends. Net debt stood at approximately 28.9 million euros, 1.8 million euros more than at the end of 2025, also influenced by the payment of these dividends. The company concluded the election of new corporate bodies for the 2026-2028 term and reinforced its participation in the Spanish company Concep, specialized in pharmacy architecture and design, raising its position from 51% to 81.39%.
Management states that the results were in line with projections despite a challenging macroeconomic environment, marked by geopolitical tensions and energy price volatility. The company maintains its conviction of growth in key indicators in the second half, with innovation and artificial intelligence, namely agent-based solutions, remaining as strategic priorities in the health area in Portugal and Spain.
